XenoPort up on Phase I data for potential autoimmune therapy

XenoPort Inc. (NASDAQ:XNPT) gained $1.71 (15%) to $12.86 on Friday after reporting Phase I pharmacokinetic and safety data for XP23829, an oral prodrug of monomethyl fumarate (MMF) that induces and activates the nuclear factor (erythroid-derived 2)-like 2 ( NRF2) pathway. XenoPort plans to develop the product for relapsing-remitting multiple sclerosis or psoriasis, with a dose-escalation Phase I trial slated to begin early next year. ...